Drug Monograph
Imatinib
Gleevec (imatinib mesylate)
Pharmacokinetic Profile
Half-Life
~18 h (parent); ~40 h (active metabolite CGP74588)
Metabolism
Hepatic; primarily CYP3A4 (also CYP1A2, 2D6, 2C9, 2C19 minor)
Protein Binding
95% (primarily albumin, α1-acid glycoprotein)
Bioavailability
~98%; take with food to reduce GI irritation
Clinical Information
Drug Class
Multi-target tyrosine kinase inhibitor
Available Doses
100 mg, 400 mg tablets; oral solution
Route
Oral (with meal and large glass of water)
Renal Adjustment
Moderate (CrCL 20–39): ↓50%; Mild (CrCL 40–59): max 600 mg
Hepatic Adjustment
Severe: ↓25% of recommended dose
Pregnancy
Can cause fetal harm — teratogenic in animals
Lactation
Present in breast milk; avoid breastfeeding
Schedule / Legal Status
Prescription only (not scheduled)
Generic Available
Yes (since 2016)
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Ph+ CML — chronic phase, newly diagnosed | Adults and pediatrics | Monotherapy | FDA Approved |
| Ph+ CML — blast crisis, accelerated phase, or CP after IFN-α failure | Adults and pediatrics | Monotherapy | FDA Approved |
| Ph+ ALL — relapsed/refractory | Adults | Monotherapy | FDA Approved |
| Ph+ ALL — newly diagnosed | Pediatrics | Combination with chemotherapy | FDA Approved |
| MDS/MPD with PDGFR gene rearrangements | Adults | Monotherapy | FDA Approved |
| Aggressive systemic mastocytosis (without D816V c-Kit mutation) | Adults | Monotherapy | FDA Approved |
| HES and/or CEL | Adults | Monotherapy | FDA Approved |
| DFSP — unresectable, recurrent, or metastatic | Adults | Monotherapy | FDA Approved |
| Kit+ GIST — unresectable and/or metastatic | Adults and pediatrics | Monotherapy | FDA Approved |
| Kit+ GIST — adjuvant after resection | Adults | Monotherapy | FDA Approved |
Imatinib revolutionized cancer treatment as the first clinically successful targeted tyrosine kinase inhibitor. Approved in 2001 after a remarkably accelerated FDA review, it transformed CML from a rapidly fatal malignancy into a manageable chronic disease with long-term survival rates exceeding 85% at 10 years. Its efficacy extends across multiple malignancies driven by BCR-ABL, c-Kit, and PDGFR signalling, making it one of the most broadly indicated oncology drugs available. The IRIS trial established imatinib as the standard first-line therapy for newly diagnosed chronic-phase CML, a position it held for over a decade.
Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Ph+ CML — chronic phase (newly diagnosed adults) | 400 mg once daily | 400 mg once daily | 800 mg/day | Escalate to 600 mg for inadequate response at 3–12 months Continue until progression or intolerance |
| Ph+ CML — accelerated phase or blast crisis (adults) | 600 mg once daily | 600 mg once daily | 800 mg/day (400 mg BID) | Escalate to 800 mg for progression or inadequate response Higher hematologic toxicity expected |
| Ph+ CML — pediatric chronic phase | 340 mg/m²/day | 340 mg/m²/day | 600 mg/day | May split into two daily doses No data in children <1 year |
| Ph+ ALL — relapsed/refractory (adults) | 600 mg once daily | 600 mg once daily | 800 mg/day | Often used as bridge to transplant |
| Kit+ GIST — unresectable/metastatic | 400 mg once daily | 400 mg once daily | 800 mg/day (400 mg BID) | Escalate if clear signs of progression Continue until progression |
| Kit+ GIST — adjuvant after resection | 400 mg once daily | 400 mg once daily | 400 mg/day | 3 years recommended (high-risk GIST) Optimal duration not fully defined |
| HES/CEL with FIP1L1-PDGFRα | 100 mg once daily | 100–400 mg once daily | 400 mg/day | Escalate from 100 to 400 mg if insufficient response Echocardiogram before starting (cardiac risk) |
| ASM without D816V c-Kit mutation | 400 mg once daily | 400 mg once daily | 400 mg/day | 100 mg if associated with eosinophilia/FIP1L1-PDGFRα |
| DFSP — unresectable/metastatic | 800 mg/day (400 mg BID) | 800 mg/day | 800 mg/day | Highest standard dose indication Use 400 mg tablet for 800 mg dosing to reduce iron exposure |
| MDS/MPD with PDGFR rearrangements | 400 mg once daily | 400 mg once daily | 400 mg/day | Confirm PDGFR rearrangement before starting |
Special Populations
| Population | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Severe hepatic impairment | 25% dose reduction | 25% reduction | Per indication | E.g., 400 mg → 300 mg; mild-moderate: no adjustment (FDA PI) |
| Moderate renal impairment (CrCL 20–39 mL/min) | 50% dose reduction | Increase as tolerated | 400 mg/day | E.g., 400 mg → 200 mg; use with caution in severe (FDA PI) |
| Mild renal impairment (CrCL 40–59 mL/min) | Per indication | Per indication | 600 mg/day | No starting dose reduction needed |
| Concomitant strong CYP3A4 inducer | Increase by ≥50% | As adjusted | 1,200 mg/day | Doses up to 1,200 mg (600 mg BID) have been given (FDA PI) Monitor clinical response carefully |
Clinical Pearl: Administration
All imatinib doses should be taken with a meal and a large glass of water to reduce GI irritation. Doses of 400 mg or 600 mg are given once daily; 800 mg is split as 400 mg twice daily. For patients who cannot swallow tablets, the tablet can be dispersed in water or apple juice (50 mL per 100 mg tablet, 200 mL per 400 mg tablet). When dosing at 800 mg or above, use the 400 mg tablet exclusively to minimise iron exposure from the tablet coating.
Pharmacology
Mechanism of Action
Imatinib is a small-molecule tyrosine kinase inhibitor that competitively binds to the ATP-binding site of several oncogenic kinases, blocking their constitutive signalling. Its primary target is the BCR-ABL fusion protein produced by the Philadelphia chromosome translocation t(9;22) in CML and Ph+ ALL, which drives uncontrolled myeloid or lymphoid proliferation. By occupying the ATP-binding pocket of BCR-ABL in its inactive conformation, imatinib prevents substrate phosphorylation and downstream proliferative signalling through pathways including RAS-MAPK, JAK-STAT, and PI3K-AKT. Beyond BCR-ABL, imatinib also potently inhibits c-Kit (the stem cell factor receptor, constitutively activated in GIST), platelet-derived growth factor receptors alpha and beta (PDGFR-α/β, involved in MDS/MPD, DFSP, and HES/CEL), and the colony-stimulating factor 1 receptor (CSF1R). This multi-kinase activity accounts for imatinib’s unusually broad spectrum of FDA-approved indications across both haematological and solid tumour malignancies.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | ~98% bioavailability; Tmax 2–4 h; food does not significantly affect extent of absorption | Take with food to reduce GI irritation (not for bioavailability); highly and reliably absorbed |
| Distribution | 95% plasma protein bound (albumin, α1-acid glycoprotein); widely distributed | High protein binding; potential for displacement interactions is low in practice |
| Metabolism | Hepatic, primarily CYP3A4; active N-desmethyl metabolite (CGP74588, ~15% of parent AUC, equipotent); minor pathways via CYP1A2, 2D6, 2C9, 2C19 | Imatinib is BOTH a CYP3A4 substrate AND inhibitor; also inhibits CYP2D6. Dual interaction potential (victim and perpetrator) |
| Elimination | t½ ~18 h (parent), ~40 h (CGP74588); 81% recovered in 7 days (68% feces, 13% urine); <25% unchanged | Long effective half-life supports once-daily dosing; predominantly hepatic elimination |
Side Effects
Side effect data below are from the IRIS trial (newly diagnosed CML-CP, imatinib 400 mg/day, N=551 vs IFN+Ara-C, N=533) unless otherwise stated (FDA PI Table 2). Rates are higher in accelerated phase and blast crisis (600 mg dose).
≥30%
Very Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Fluid retention / edema | 61.7% | Superficial edema 59.9%; periorbital and lower limb most common; dose- and age-related; severe in 2.5% |
| Nausea | 49.5% | Usually mild (Grade 3/4: 1.3%); taking with food and large glass of water reduces severity |
| Muscle cramps | 49.2% | Characteristic of imatinib; often nocturnal; electrolyte supplementation (calcium, magnesium) may help |
| Musculoskeletal pain | 47.0% | Grade 3/4 in 5.4%; may require dose adjustment |
| Diarrhea | 45.4% | Similar to IFN+Ara-C (43.3%); Grade 3/4 in 3.3% |
| Rash | 40.1% | Usually mild maculopapular; Grade 3/4 in 2.9%; monitor for severe bullous reactions |
| Fatigue | 38.8% | Much lower than IFN+Ara-C (67.0%); rarely dose-limiting |
| Headache | 37.0% | Grade 3/4 rare (0.5%) |
| Abdominal pain | 36.5% | Take with food; Grade 3/4 in 4.2% |
| Joint pain | 31.4% | Grade 3/4 in 2.5% |
| Nasopharyngitis | 30.5% | Grade 3/4 essentially absent |
10–30%
Common
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Hemorrhage (all sites) | 28.9% | Grade 3/4 in 1.8%; much higher in AP/BC (up to 53%); GI source common in GIST |
| Myalgia | 24.1% | Grade 3/4 in 1.5%; lower than IFN+Ara-C (38.8%) |
| Vomiting | 22.5% | Grade 3/4 in 2.0% |
| Upper respiratory infection | 21.2% | Grade 3/4 rare (0.2%) |
| Cough | 20.0% | Grade 3/4 rare (0.2%) |
| Dizziness | 19.4% | Caution with driving and machinery (FDA warning) |
| Dyspepsia | 18.9% | Take with food to reduce GI symptoms |
| Pyrexia | 17.8% | Higher in AP/BC (41%) |
| Weight increased | 15.6% | May reflect fluid retention; Grade 3/4 in 2.0% |
| Depression | 14.9% | Much lower than IFN+Ara-C (35.8%) |
| Insomnia | 14.7% | Lower than IFN+Ara-C (18.6%) |
| Bone pain | 11.3% | Grade 3/4 in 1.6% |
Serious
Serious (Regardless of Frequency)
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe fluid retention (pleural effusion, pericardial effusion, pulmonary edema, ascites) | 1.3–6% (dose/phase dependent) | Weeks to months; more common at higher doses and in elderly | Interrupt imatinib; diuretics; supportive care; resume at reduced dose after resolution |
| Grade 3/4 neutropenia | 16.7% (CP-CML); 61–64% (AP/BC) | First 2–4 weeks | Hold until ANC ≥1.5×10&sup9;/L then resume; reduce dose per Table 1 in FDA PI if recurrent |
| Grade 3/4 thrombocytopenia | 8.9% (CP-CML); 44–62% (AP/BC) | First 2–4 weeks | Hold until platelets ≥75×10&sup9;/L; reduce dose if recurrent |
| Hepatotoxicity (Grade 3/4 ALT/AST elevation) | 5.2% (CP-CML); 5–6% (AP/BC) | Variable; can occur at any time | Hold if bilirubin >3× ULN or transaminases >5× ULN; resume at reduced dose when resolved. Fatal liver failure reported |
| CHF / left ventricular dysfunction | 0.7% (CP-CML) | Variable; more common with advanced age/comorbidities | Monitor patients with cardiac risk factors; manage per heart failure guidelines |
| Grade 3/4 hemorrhage | 1.8% (CML); 5–12.9% (GIST) | Any time; GI tumour sites are source in GIST | Avoid anticoagulants; use LMWH if anticoagulation needed (not warfarin); evaluate bleeding source |
| GI perforation | Rare; fatalities reported | Variable | Urgent surgical evaluation; discontinue imatinib |
| Stevens-Johnson syndrome / erythema multiforme | Rare (post-marketing) | Weeks to months | Discontinue; may cautiously rechallenge at lower dose with steroid cover after resolution |
| Tumor lysis syndrome | Rare; fatal cases reported | Days after initiation in high-burden disease | Hydrate; correct dehydration and hyperuricemia before starting; close monitoring |
| Growth retardation in children | Reported (frequency not quantified) | During prolonged treatment | Monitor growth parameters regularly; long-term effects unknown |
| Renal toxicity (eGFR decline) | Common; median eGFR 85→69 mL/min at 60 months | Progressive over years | Evaluate renal function at baseline and during therapy; attention to diabetes, hypertension, CHF |
Discontinuation
Discontinuation Rates
IRIS Trial (Newly Diagnosed CP-CML)
2.4% drug-related AE withdrawal
Top reasons: Hepatotoxicity, cytopenias, rash, fluid retention
Other CML Phases
4–5% CP after IFN: 4%, AP: 4%, BC: 5%
Context: Higher toxicity at 600 mg dose reflects more advanced disease
Managing Fluid Retention
Fluid retention is the hallmark side effect of imatinib and ranges from mild periorbital edema (very common) to life-threatening pleural effusion or pulmonary edema (uncommon but serious). Risk increases with dose, age >65, and advanced disease phase. Regular weight monitoring is essential — rapid weight gain should trigger evaluation for serous effusions. Management involves dose interruption, diuretics, and supportive care, with dose resumption at a lower level after resolution.
Drug Interactions
Imatinib has extensive drug interaction potential because it is both a substrate and an inhibitor of CYP3A4, and also inhibits CYP2D6. This dual “victim-and-perpetrator” profile demands careful medication review before starting therapy and at every prescription change.
MajorStrong CYP3A4 Inducers (Rifampin, Phenytoin, Carbamazepine, St. John’s Wort)
MechanismAccelerate CYP3A4-mediated clearance of imatinib
EffectRifampin increases imatinib oral clearance 3.8-fold, significantly reducing Cmax and AUC; EIAEDs reduce AUC by 73%
ManagementIncrease imatinib dose by ≥50% (up to 1,200 mg/day given as 600 mg BID); monitor response closely; consider alternative agents with less induction potential
FDA PIMajorWarfarin
MechanismImatinib inhibits CYP3A4 and CYP2C9, potentially altering warfarin metabolism; imatinib also causes thrombocytopenia
EffectUnpredictable INR changes; increased bleeding risk from dual pharmacokinetic and pharmacodynamic mechanisms
ManagementAvoid warfarin; use LMWH or unfractionated heparin for anticoagulation (FDA PI recommendation)
FDA PIModerateStrong CYP3A4 Inhibitors (Ketoconazole, Itraconazole, Clarithromycin, Grapefruit Juice)
MechanismInhibit CYP3A4-mediated metabolism of imatinib
EffectKetoconazole increased imatinib mean Cmax by 26% and AUC by 40%
ManagementUse with caution; monitor for increased imatinib toxicity; avoid grapefruit juice
FDA PIModerateCYP3A4 and CYP2D6 Substrates
MechanismImatinib inhibits both CYP3A4 and CYP2D6, raising levels of their substrates
EffectIncreased exposure to narrow-TI drugs (e.g., cyclosporine, simvastatin, certain opioids, metoprolol, tricyclics)
ManagementMonitor levels/effects of concomitant CYP3A4/2D6 substrates; dose-adjust as needed; comprehensive medication review essential
FDA PIModerateAcetaminophen (Paracetamol)
MechanismImatinib inhibits O-glucuronidation of paracetamol via UGT1A1
EffectIncreased risk of hepatotoxicity with chronic concomitant use, particularly at imatinib doses >400 mg/day
ManagementLimit chronic paracetamol use; monitor liver function closely
FDA PIModerateLevothyroxine (in Thyroidectomy Patients)
MechanismMechanism not fully elucidated; may involve increased levothyroxine clearance
EffectClinical hypothyroidism reported in thyroidectomy patients on levothyroxine replacement
ManagementMonitor TSH closely in thyroidectomy patients; adjust levothyroxine dose as needed
FDA PIMonitoring
- Complete Blood CountWeekly × 1 month, biweekly × 1 month, then every 2–3 months
RoutineGrade 3/4 neutropenia 16.7%, thrombocytopenia 8.9%, anemia 4.4% in CP-CML. Much higher in AP/BC. Dose modification per FDA PI Table 1 if ANC <1.0×10&sup9;/L or platelets <50×10&sup9;/L. - Liver FunctionBaseline, then monthly or as indicated
RoutineMonitor transaminases, bilirubin, alkaline phosphatase. Hold imatinib if bilirubin >3× ULN or transaminases >5× ULN. Fatal liver failure has been reported. Extra vigilance when combined with hepatotoxic chemotherapy. - Weight & Fluid StatusEach clinic visit; daily at home during first months
RoutineWeigh regularly; investigate rapid weight gain (>2 kg in 1 week) for serous effusions. Severe fluid retention in 1.3–13% depending on indication/dose. - Renal FunctionBaseline, then periodically
RoutineMedian eGFR declined from 85 to 69 mL/min/1.73 m² at 60 months. Attention to risk factors (diabetes, hypertension, CHF). Dose adjust for CrCL <60 mL/min. - Cardiac FunctionBaseline in patients with cardiac risk; as clinically indicated
Trigger-basedCHF/LV dysfunction in 0.7% (CP-CML). Higher risk in elderly and those with cardiac history. Echo and troponin BEFORE starting in HES/CEL/ASM with eosinophilia (cardiogenic shock risk). - TSHIf thyroidectomy patient on levothyroxine
Trigger-basedHypothyroidism reported in thyroidectomy patients during imatinib treatment. Monitor TSH and adjust levothyroxine as needed. - Growth (Pediatric)Every 3–6 months
RoutineGrowth retardation reported in children on prolonged imatinib. Monitor height, weight, and growth velocity. Long-term effects unknown. - Molecular Response (CML)Q3 months until MMR, then Q3–6 months
RoutineBCR-ABL1 transcript levels by quantitative RT-PCR (IS). Failure milestones per NCCN/ELN guidelines should prompt consideration of dose escalation or switch to second-generation TKI.
Contraindications & Cautions
Absolute Contraindications
- None listed in the FDA prescribing information. This is unusual for an oncology drug and reflects imatinib’s generally manageable toxicity profile. However, the absence of formal contraindications does not negate the importance of the extensive warnings and precautions.
Relative Contraindications (Specialist Input Recommended)
- Pregnancy. Imatinib is teratogenic in rats (exencephaly, encephalocele) at doses equal to the maximum human dose. Post-marketing reports of spontaneous abortions and congenital anomalies. Effective contraception required during treatment and for 14 days after the last dose.
- Pre-existing CHF or severe cardiac disease. CHF and LV dysfunction reported; cardiac adverse reactions more frequent in elderly and those with comorbidities.
- HES/CEL/ASM with occult cardiac eosinophilic infiltration. Cardiogenic shock/LV dysfunction reported at imatinib initiation due to eosinophil degranulation. Require echocardiogram, serum troponin, and consider prophylactic systemic steroids (1–2 mg/kg) for 1–2 weeks with imatinib initiation.
- Severe renal impairment. Limited data; use with caution; a dose of 100 mg/day was tolerated in two patients.
Use with Caution
- Hepatic impairment. Severe: reduce dose by 25%. Fatal liver failure reported; monthly LFT monitoring required.
- Concomitant anticoagulation. Use LMWH or standard heparin, not warfarin.
- High tumor burden. Risk of tumor lysis syndrome; correct dehydration and hyperuricemia before starting.
- Lactation. Imatinib and its active metabolite are present in human breast milk. Avoid breastfeeding during treatment and for 1 month after the last dose.
- Driving and operating machinery. Reports of motor vehicle accidents; dizziness, blurred vision, and somnolence may occur.
FDA Warning — Embryo-Fetal Toxicity
Imatinib Can Cause Fetal Harm
Imatinib was teratogenic in rats at doses approximately equal to the maximum human dose (800 mg/day based on BSA). Post-marketing reports include spontaneous abortions and congenital anomalies. Advise females of reproductive potential to use effective contraception (methods with <1% pregnancy rates) during treatment and for 14 days after stopping (FDA PI Section 5.10).
FDA Warning — Severe Hepatotoxicity
Fatal Liver Failure Has Been Reported
Hepatotoxicity, occasionally severe and including fatal liver failure and cases requiring liver transplant, may occur with both short-term and long-term imatinib use. Assess liver function before initiation and monthly thereafter. When combined with chemotherapy, monitor more frequently due to increased hepatotoxic risk (FDA PI Section 5.4).
Patient Counselling
Purpose of Therapy
Imatinib works by blocking specific proteins (tyrosine kinases) that cancer cells depend on to grow and survive. In CML, it targets the BCR-ABL protein produced by the Philadelphia chromosome; in GIST, it targets the c-Kit protein. By switching off these growth signals, imatinib can bring the disease under control, often allowing patients to live with their condition as a manageable chronic illness. For CML, treatment is typically long-term and may continue for years as long as the disease remains controlled.
How to Take
Take imatinib with a meal and a large glass of water. Doses of 400 mg or 600 mg are taken once daily; if prescribed 800 mg, take 400 mg in the morning and 400 mg in the evening. If unable to swallow tablets, they can be dissolved in water or apple juice. Do not crush the tablets — disperse the whole tablet in the liquid and drink immediately. Never take a double dose to make up for a missed one.
Swelling & Fluid Retention
Tell patientPuffiness around the eyes, swollen ankles, or rapid weight gain are common and usually mild. Weigh yourself daily during the first few months. Reducing salt intake may help. Most swelling can be managed without stopping the medication.
Call prescriberIf you gain more than 2 kg (4.5 lbs) in one week, develop shortness of breath, chest pain, persistent cough, or notice rapidly worsening swelling. These could indicate serious fluid accumulation.
Nausea & GI Symptoms
Tell patientNausea, vomiting, and diarrhea are common early in treatment but usually improve over time. Always take the tablet with a substantial meal and a full glass of water. Eating smaller, more frequent meals may help.
Call prescriberIf vomiting prevents you from keeping the medication down, or if you develop bloody or black stools, or severe abdominal pain.
Muscle Cramps
Tell patientMuscle cramps affect nearly half of patients and are often felt in the calves, feet, or hands, especially at night. Staying well hydrated, stretching regularly, and ensuring adequate calcium and magnesium intake may provide relief.
Call prescriberIf cramps are severe enough to interfere with sleep or daily function, or if you develop muscle weakness or dark-coloured urine.
Bleeding Risk
Tell patientImatinib can lower blood platelets, increasing the risk of bruising or bleeding. Avoid contact sports and be cautious with sharp objects. Inform your dentist and any other doctors that you are taking imatinib. Do not take aspirin or ibuprofen without asking your prescriber first.
Call prescriberIf you experience unusual bleeding (nosebleeds that won’t stop, blood in urine or stool, unexplained bruising), or if you feel very tired or short of breath (signs of low blood counts).
Pregnancy & Driving
Tell patientImatinib can harm an unborn baby. Use reliable contraception during treatment and for at least 14 days after stopping. Do not breastfeed during treatment. Some patients experience dizziness or blurred vision — use caution when driving or operating machinery, especially early in treatment.
Call prescriberImmediately if pregnancy is suspected or confirmed. Also report persistent visual changes or dizziness that affects daily activities.
Sources
Regulatory (PI / SmPC)
- GLEEVEC (imatinib mesylate) Tablets. Full Prescribing Information. Novartis Pharmaceuticals Corporation. Revised 03/2022. FDA LabelPrimary regulatory source for all dosing, pharmacokinetics, adverse reaction incidence rates, contraindications, and drug interaction data.
Key Clinical Trials
- O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004. DOIIRIS trial initial results establishing imatinib superiority over IFN+Ara-C for newly diagnosed CP-CML.
- Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–2417. DOIIRIS 5-year update confirming sustained complete cytogenetic response in 87% and estimated OS of 89%.
- Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–927. DOIIRIS 10-year analysis demonstrating estimated OS of 83.3% and confirming imatinib as transformative CML therapy.
- Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472–480. DOILandmark trial demonstrating imatinib efficacy in KIT-positive advanced GIST with 54% partial response rate.
- Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307(12):1265–1272. DOISSGXVIII/AIO trial establishing 3 years of adjuvant imatinib as superior to 1 year in high-risk GIST.
Guidelines
- Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984. DOIELN 2020 CML management recommendations including response milestones, TKI selection, and treatment-free remission criteria.
- Casali PG, Blay JY, Abecassis N, et al. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines. Ann Oncol. 2022;33(1):20–33. DOIESMO GIST guideline covering imatinib dosing, duration, and mutational considerations in adjuvant and metastatic settings.
Mechanistic / Basic Science
- Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561–566. DOIFoundational preclinical study demonstrating selective inhibition of BCR-ABL by imatinib (STI571) in CML cell lines.
Pharmacokinetics / Special Populations
- Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879–894. DOIComprehensive PK review covering absorption, distribution, metabolism, elimination, drug interactions, and special populations.
- Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251–2259. DOIENESTnd trial comparing imatinib with nilotinib; source for comparative adverse event rates in newly diagnosed CP-CML.
- Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–1037. DOIPhase 1 study establishing imatinib safety, dose-response, and hematologic response rates in CML after IFN failure.